Tennessee is currently home to 1987 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Toyos Clinic, Nashville, Tennessee
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT05200364
Recruiting
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/01/2022
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Tennessee Oncology, Chattanooga, Tennessee
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates
The JULI Registry--Hemp and Cannabis Observational Registry
NCT04726254
Recruiting
The JuLi Registry seeks to fill some of the gaps associated with the clinical use of CBD (cannabidiol) and other cannabinoid formulations including THC and others. The overarching goal of this Registry is to rapidly advance research and understanding of the use of cannabis and hemp-based formulations, in the clinical community setting, when it is utilized to manage the symptoms of cancer treatment and other underlying health issues. These symptoms include nausea, neuropathy, and sleeplessness an... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
07/15/2022
Locations: Nashville Breast Center, Nashville, Tennessee
Conditions: Chronic Pain, Appetite Disorders, Neuropathy, Menopausal Syndrome, Anxiety, Sleep Disturbance, Nausea
Register for Updates
MIP Versus PCNL for Kidney Stone Disease
NCT04767919
Recruiting
The decision to use standard percutaneous nephrolithotomy (PCNL) versus mini-percutaneous nephrolithotomy (MIP) has been a subject of much debate in the urological community. The investigators propose a randomized controlled trial to compare the operative outcomes and complications of mini-percutaneous nephrolithotomy (mini-PCNL) versus standard PCNL for renal stones. The results of this study will help guide the decision making regarding these two procedures in the US population and provide fur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Kidney Stone
Register for Updates
Impact of Jump Start Nutrition Program on Weight Loss and Associated Measures
NCT05443269
Recruiting
The purpose of the proposed study is to evaluate the impact of the Jump Start program to facilitate weight loss in a sample of overweight and obese men and women. The study will not only evaluate weight loss and changes in body-shape but will also assess the type of weight lost (fat vs. lean mass) and other health measures affected by obesity including lipids, glucose, insulin, resting heart rate and blood pressure, and perceived wellness. This study will contribute to the general weight loss li... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/29/2022
Locations: Center for Nutraceutical and Dietary Supplement Research, Memphis, Tennessee
Conditions: Weight Loss
Register for Updates
Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults
NCT01547429
Recruiting
This study will determine the safety and effectiveness of the Artisan Aphakia Lens when used as a secondary implant to correct aphakia in adults.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/24/2022
Locations: University of Tennessee, Hamilton Eye Clinic, Memphis, Tennessee
Conditions: Aphakia
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Saint Jude Children's Research Hospital (Pediatrics only), Memphis, Tennessee
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
NCT04900844
Recruiting
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
06/16/2022
Locations: Ballad CVA Heart Institute, Kingsport, Tennessee
Conditions: Carotid Artery Stenosis
Register for Updates
Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients
NCT05264545
Recruiting
A 510k approved dental device for subjects requiring single or multiple tooth replacement with implants where immediate restoration/loading is preferred.
Gender:
All
Ages:
25 years and above
Trial Updated:
05/25/2022
Locations: Perio & Implant Associates of Middle TN, Nashville, Tennessee
Conditions: Partially Edentulous Maxilla or Mandible
Register for Updates
ColoCare Study - Colorectal Cancer Cohort
NCT02328677
Recruiting
ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
05/22/2022
Locations: University of Tennessee, Knoxville, Tennessee
Conditions: Colorectal Cancer
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates